Wealthfront Advisers LLC Takes $1.09 Million Position in Moderna, Inc. $MRNA

Posted by George Bondi on Aug 22nd, 2026

Wealthfront Advisers LLC acquired a new stake in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 15,621 shares of the company’s stock, valued at approximately $1,094,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. AQR Capital Management LLC acquired a new position in Moderna in the 1st quarter worth about $415,000. NewEdge Advisors LLC boosted its stake in shares of Moderna by 732.7% during the first quarter. NewEdge Advisors LLC now owns 11,575 shares of the company’s stock valued at $328,000 after purchasing an additional 10,185 shares in the last quarter. United Services Automobile Association acquired a new stake in shares of Moderna during the first quarter valued at about $230,000. Focus Partners Wealth grew its holdings in shares of Moderna by 58.7% during the first quarter. Focus Partners Wealth now owns 23,547 shares of the company’s stock worth $668,000 after purchasing an additional 8,706 shares during the last quarter. Finally, American Century Companies Inc. grew its holdings in shares of Moderna by 5.2% during the second quarter. American Century Companies Inc. now owns 48,859 shares of the company’s stock worth $1,348,000 after purchasing an additional 2,410 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Trading Up 8.8%

Shares of MRNA stock opened at $145.07 on Friday. Moderna, Inc. has a 1-year low of $22.28 and a 1-year high of $176.66. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. The stock has a market cap of $57.92 billion, a price-to-earnings ratio of -18.16 and a beta of 0.91. The stock has a 50-day moving average of $68.49 and a 200-day moving average of $56.10.

Moderna (NASDAQ:MRNA – Get Free Report) last posted its quarterly earnings data on Friday, July 31st. The company reported ($1.97) EPS for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The company had revenue of $145.00 million for the quarter, compared to analyst estimates of $102.93 million. During the same period in the previous year, the firm earned ($2.13) earnings per share. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. On average, equities research analysts forecast that Moderna, Inc. will post -6.18 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on MRNA shares. Citigroup upped their price objective on Moderna from $41.00 to $60.00 and gave the company a “neutral” rating in a research note on Monday, August 3rd. Wolfe Research reiterated an “underperform” rating and set a $25.00 target price on shares of Moderna in a research report on Monday, July 20th. JPMorgan Chase & Co. boosted their target price on shares of Moderna from $40.00 to $77.00 and gave the stock an “underweight” rating in a report on Friday. Loop Capital set a $135.00 price target on shares of Moderna in a research report on Wednesday. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $130.00 price target on shares of Moderna in a research note on Wednesday. Four investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $69.50.

View Our Latest Report on MRNA

More Moderna News

Here are the key news stories impacting Moderna this week:

Positive Sentiment: Investors are assigning substantial commercial potential to the cancer program. Jefferies reportedly estimates as much as $54 billion in peak global sales and raised its price target to $170, while coverage highlighted the possibility that the trial could establish an oncology opportunity comparable to Merck’s Keytruda franchise. Jefferies sees $54 billion peak sales for Moderna cancer therapy
Positive Sentiment: The favorable Phase 3 outcome has triggered analyst upgrades, including William Blair moving Moderna to Outperform and Bank of America raising its rating to Neutral. The stock also reached a new 12-month high amid renewed enthusiasm for mRNA-based cancer treatments. Moderna raised to Outperform at William Blair
Neutral Sentiment: Trading has been exceptionally volatile for a third consecutive session. Analysts attribute the sharp swings partly to heavy short interest and a subsequent short squeeze, while options activity suggests elevated volatility may persist even without new clinical information. Moderna rallies as mRNA trading whipsaws
Negative Sentiment: Valuation concerns remain significant after the recent surge. JPMorgan raised its price target to $77 but retained an Underweight rating, implying substantial downside from current levels. Commentary also cautioned that the clinical success does not eliminate development, regulatory, manufacturing, commercialization, and pipeline risks for Moderna or other mRNA companies. JPMorgan raises Moderna price target but keeps Underweight rating

Insider Buying and Selling

In other Moderna news, insider Shannon Thyme Klinger sold 3,471 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $50.00, for a total transaction of $173,550.00. Following the completion of the transaction, the insider owned 67,468 shares in the company, valued at approximately $3,373,400. This trade represents a 4.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 53,336 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the completion of the transaction, the president owned 1,483,848 shares in the company, valued at $76,225,271.76. This trade represents a 3.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 10.80% of the company’s stock.

Moderna Company Profile

(Free Report)

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.